|
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32) Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32) Clinical research trials and Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32) healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32). Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32) Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32) clinical trial. Human subjects often receive the most effective healthcare possible for their Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32) condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32)  Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32)
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32)
For Condition: Cancer
Status: Recruiting
Sponsor(s): National Center for Research Resources (NCRR) ,
Synopsis: The purpose of this clinical trial is to establish the safest doses for the combination of a farnesyl transferase inhibitor, R115777 plus topotecan in patients with advanced solid tumors, previously treated or beyond standard therapy of clinical benefit. Maximum tolerated dose, dose limiting toxicity and the activity of this combination will be assessed. This chemotherapy regimen is a two-pronged attack at the way cancer cells replicate. R115777 is a compound that may inhibit cancer cell growth by interfering with the p21 ras oncogene, while topotecan, a topoisomerase-1 inhibitor, works on cancer cells not subject to control by the ras oncogene. Animal studies suggest that the combination may be synergistic. Another advantage is that R115777 can be taken by mouth.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients with advanced solid tumors with previous treatment or beyond standard therapy of significant clinical benefit - Therapy with no more than 3 prior chemotherapy regimens - Radiotherapy to less than 25% of bone marrow volume (no pelvic radiation) - Adequate organ function - Recovery from the effects of prior chemotherapy and radiation therapy, with at least a 4 week interval. All prior toxicities should have resolved to baseline prior to entry into the study. - Good performance status - Anticipate life expectancy of at least 6 months - Not pregnant or lactating. - Sexually active men and women of childbearing age must use adequate contraception. - Be able to give signed, written informed consent. - No gastrointestinal condition that could affect the absorption of the drug - No active infection requiring systemic medical therapy one week prior to chemotherapy
Total Enrollment:
Location and Contact Information:
Kaplan Comprehensive Cancer Center *Recruiting*
New York City, New York, 10016
United States
Recruiting Madeline Peyton 212-263-6485
Additional Information:
Study ID Numbers: NCRR-M01RR00096-1001; M01RR00096
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006199
Other Cancer Studies:
1. Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
2. Mindfulness-Based Art Therapy for Cancer Patients
3. High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
4. Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors
5. Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Related Studies:
Other Cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Topotecan (NYU 99-32)
|
|
|
|
|
|
|
|
